Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Browse trials for

• Glaucoma 1,818
• Ocular Hypertension 649
• Hypertension 6,689

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's enrollment of 604 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Lead sponsor

Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.

Study arms

• Experimental
  1

  Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

  Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

• Active comparator
  2

  Concurrent Brimonidine 0.2% and 0.5% Timolol

  Drug: Concurrent brimonidine 0.2% and 0.5% timolol

Interventions

• DrugBrimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

  Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)

  Also known as: COMBIGAN™

• DrugConcurrent brimonidine 0.2% and 0.5% timolol

  Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)

Primary outcomes

1. Adverse Events

   Time frame: Day 10

Related links

• Link to Clinical Trial Results ↗